Main Management ETF Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Main Management ETF Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-792,750	Closed	-$60.4M	–	40
2023 Q1	$60.4M	Buy	792,750 +21,140	+3%	+$1.75M	5.13%	10
2022 Q4	$64M	Buy	771,610 +295,865	+62%	+$24M	5.98%	8
2022 Q3	$37.7M	Buy	475,745 +3,860	+0.8%	+$325K	4.33%	11
2022 Q2	$35M	Sell	471,885 -965	-0.2%	-$72.4K	3.89%	11
2022 Q1	$42.5M	Buy	472,850 +297,530	+170%	+$27.5M	3.95%	11
2021 Q4	$19.6M	Buy	175,320 +9,000	+5%	+$1.09M	1.72%	15
2021 Q3	$20.9M	Buy	166,320 +7,560	+5%	+$974K	2.11%	15
2021 Q2	$21.5M	Buy	158,760 +8,280	+6%	+$1.09M	2.24%	15
2021 Q1	$20.4M	Sell	150,480 -53,570	-26%	-$8.02M	2.41%	15
2020 Q4	$28.7M	Sell	204,050 -550	-0.3%	-$70.4K	4.5%	12
2020 Q3	$22.8M	Sell	204,600 -5,500	-3%	-$617K	4.02%	11
2020 Q2	$23.5M	Buy	210,100 +9,350	+5%	+$921K	4.44%	11
2020 Q1	$15.5M	Sell	200,750 -550	-0.3%	-$48.7K	3.72%	10
2019 Q4	$19.1M	Buy	201,300 +8,800	+5%	+$761K	3.71%	11
2019 Q3	$14.7M	Sell	192,500 -107,200	-36%	-$8.91M	3.19%	11
2019 Q2	$26.3M	Buy	299,700 +18,000	+6%	+$1.54M	6.06%	7
2019 Q1	$25.5M	Buy	281,700 +15,300	+6%	+$1.3M	5.92%	7
2018 Q4	$19.1M	Buy	266,400 +15,300	+6%	+$1.23M	5.34%	7
2018 Q3	$24.1M	Buy	251,100 +29,700	+13%	+$2.88M	6.06%	7
2018 Q2	$21.1M	Buy	221,400 +33,300	+18%	+$3.06M	6.27%	7
2018 Q1	$16.5M	Buy	188,100 +30,600	+19%	+$2.79M	5.85%	7
2017 Q4	$13.4M	Buy	+157,500	New	+$13.2M	5.72%	7

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Main Management ETF Advisors's XBI Position: Q2 2023 in Review

Main Management ETF Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2023, closing a stake of 792,750 shares — an estimated $60.4M sold.

Main Management ETF Advisors first reported a position in XBI in Q4 2017 and held it in 22 quarters. The position peaked at $64M in Q4 2022. 712 funds tracked by Wall St. Rank hold XBI as of Q2 2023.

Main Management ETF Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2023 after selling out during the quarter.
Main Management ETF Advisors sold 792,750 State Street SPDR S&P Biotech ETF shares in Q2 2023, an estimated $60.4M.
Main Management ETF Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and held it in 22 quarters.
Main Management ETF Advisors's State Street SPDR S&P Biotech ETF position peaked at $64M in Q4 2022.
712 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2023.

Based on Main Management ETF Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.